High-Dose Rosuvastatin Treatment for Multifocal Stroke in Trauma-Induced Cerebral Fat Embolism Syndrome: A Case Report



      Fat embolism syndrome is a life-threatening condition with treatment centering on the provision of excellent supportive care and early fracture fixation. No pharmacologic intervention has yet shown any clear benefit. We used high-dose rosuvastatin specifically for its anti-inflammatory effects to treat a patient with severe fat embolism syndrome. We also suggest that magnetic resonance imaging and transcranial Doppler studies are helpful in establishing the diagnosis and for monitoring the patient's course.


      A 17-year-old boy developed severe cerebral fat embolism syndrome with multifocal strokes after sustaining bilateral femur fractures.


      In spite of profound and prolonged neurological impairment, our patient experienced dramatic recovery by the time he was discharged from inpatient rehabilitation several weeks after his initial injury. Magnetic resonance imaging revealed the classic “starfield” pattern of infarcts on diffusion-weighted sequences early in the illness. Additionally, serial transcranial Doppler studies demonstrated dramatically elevated microembolic events that resolved completely during the course of treatment.


      We feel that the acute administration of high-dose rosuvastatin early in the development of our patient's illness may have contributed to his ultimate recovery. Therapeutic guidelines cannot be extrapolated from a single patient, but our experience suggests that statin therapy could be potentially beneficial for individuals with severe fat embolism syndrome, and this approach deserves further clinical evaluation. Additionally, the diagnosis and monitoring of cerebral involvement in fat embolism syndrome is facilitated by both magnetic resonance imaging and transcranial Doppler studies.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Pediatric Neurology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bulger E.M.
        • Smith D.G.
        • Maier R.V.
        • Jurkovich G.J.
        Fat embolism syndrome. A 10-year review.
        Arch Surg. 1997; 132: 435-439
        • Posner J.B.
        • Saper C.B.
        • Schiff N.
        • Plum F.
        Plum and Posner's Diagnosis of Stupor and Coma.
        4th Edition. Oxford University Press, 2007
        • Schnaid E.
        • Lamprey J.M.
        • Viljoen M.J.
        • Joffe B.I.
        • Seftel H.C.
        The early biochemical and hormonal profile of patients with long bone fractures at risk of fat embolism syndrome.
        J Trauma. 1987; 27: 309-311
        • Parizel P.M.
        • Demey H.E.
        • Veeckmans G.
        • et al.
        Early diagnosis of cerebral fat embolism syndrome by diffusion-weighted MRI (starfield pattern).
        Stroke. 2001; 32: 2942-2944
        • Aravapalli A.
        • Fox J.
        • Lazaridis C.
        Cerebral fat embolism and the “starfield” pattern: a case report.
        Cases J. 2009; 2: 212
        • Forteza A.M.
        • Koch S.
        • Campo-Bustillo I.
        • et al.
        Transcranial Doppler detection of cerebral fat emboli and relation to paradoxical embolism: a pilot study.
        Circulation. 2011; 123: 1947-1952
        • Mellor A.
        • Soni N.
        Fat embolism.
        Anaesthesia. 2001; 56: 145-154
        • Sen R.K.
        • Tripathy S.K.
        • Krishnan V.
        Role of corticosteroid as a prophylactic measure in fat embolism syndrome: a literature review.
        Musculoskelet Surg. 2012; 96: 1-8
        • Butteriss D.J.
        • Mahad D.
        • Soh C.
        • Walls T.
        • Weir D.
        • Birchall D.
        Reversible cytotoxic cerebral edema in cerebral fat embolism.
        AJNR Am J Neuroradiol. 2006; 27: 620-623
        • Sandercock P.A.
        • Soane T.
        Corticosteroids for acute ischaemic stoke.
        Cochrane Database Syst Review. 2011;
        • Lefer A.M.
        • Scalia R.
        • Lefer D.J.
        Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease.
        Cardiovasc Res. 2001; 49: 281-287
        • Correia L.C.
        • Spósito A.C.
        • Lima J.C.
        • et al.
        Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction.
        Am J Cardiol. 2003; 92: 298-301
        • Thongtang N.
        • Ai M.
        • Otokozawa S.
        • et al.
        Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.
        Am J Cardiol. 2011; 107: 387-392
        • Pruefer D.
        • Makowski J.
        • Schnell M.
        • et al.
        Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin.
        Circulation. 2002; 106: 2104-2110
        • Kronzon I.
        • Saric M.
        Cholesterol embolization syndrome.
        Circulation. 2010; 122: 631-641
        • Tunick P.A.
        • Nayar A.
        • Goodkin G.M.
        • et al.
        Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque.
        Am J Cardiol. 2002; 90: 1320-1325
        • Willey J.Z.
        • Elkind M.S.
        3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases.
        Arch Neurol. 2010; 67: 1062-1067
        • Elkind M.S.
        Statins as acute-stroke treatment.
        Int J Stroke. 2006; 1: 224-225
        • Debasish M.
        • Shaikh S.
        • Solanki D.
        • Gaurav K.
        Safety of statins.
        Indian J. Endocrinol Metab. 2013; 17: 636-646